malaria/fever

TECHNICAL FIELD The present invention relates to an antigenic polypeptide derived from SERA (serine-repeat antigen) of Plasmodium falciparum, to a process for purification of the polypeptide, and to malaria vaccine and diagnostic agent using as an active component the purified antigen obtained from

TECHNICAL FIELD The present invention relates to an antigenic polypeptide derived from SERA (serine-repeat antigen) of Plasmodium falciparum, to a process for purification of the polypeptide, and to malaria vaccine and diagnostic agent using as an active component the purified antigen obtained from

FIELD OF INVENTION The present invention relates generally to novel therapeutic compositions, and more specifically to herbal compositions and methods of making and combining artemisinin and berberine to deliver active therapeutic substances for treatment and prevention of diseases and infections

FIELD OF INVENTION The present invention relates generally to novel therapeutic compositions, and more specifically to herbal compositions and methods of making and combining artemisinin and berberine to deliver active therapeutic substances for treatment and prevention of diseases and infections

The present invention relates to pharmaceutical, veterinary or dietary compositions and the use thereof for a method of treatment or prophylaxis of depressed or inadequate intracellular pyridoxal phosphate levels in a human or animal patient resulting from a condition, wherein the pyridoxine

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

OF THE INVENTION The present invention is directed to larvicide formulation and methods of administration thereof for killing the instars larval stages and pupae in about two hours and fifteen minutes, respectively; with no impact on the environment. In particular, the larvicide formulation and

DESCRIPTION Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa. The invention relates to the use of inhibitors of the cellular sodium-hydrogen exchanger for the production of a pharmaceutical for the

FIELD OF THE INVENTION The present invention relates to compounds and compositions for controlling blood-ingesting pests, and methods of making and using thereof. In specific embodiments, the compounds are mosquitocides. BACKGROUND OF THE INVENTION Many blood-ingesting pests are known to feed on